Develops a first-in-class inhaled therapeutic using targeted anti-inflammatory cannabinoids as a corticosteroid alternative for patients with pulmonary inflammatory diseases (COPD, idiopathic pulmonary fibrosis, COVID-19, cystic fibrosis, asthma, bronchitis, ARDS). Uses a proprietary polarity-adaptive transport mechanism to modulate the immune response and reduce lung inflammation by targeting the inflammatory cascade at multiple levels.